Reply to “Urinary Tract Infections: Resistance Is Futile”

Rachel M. Kenney,^a Kelli A. Cole,^b Mary Beth Perri,^c Lisa E. Dumkow,^d Linoj P. Samuel,^e Marcus J. Zervos,^{c,f,g} Susan L. Davis^{a,h}

Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA^a; Department of Pharmacy Services, University of Toledo Medical Center, Toledo, Ohio, USA^b; Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA^c; Department of Pharmacy Services, Mercy Health Saint Mary's, Grand Rapids, Michigan, USA^d; Department of Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, Michigan, USA^e; Division of Infectious Diseases, Henry Ford Health System, Detroit, Michigan, USA^f; Wayne State University School of Medicine, Detroit, Michigan, USA^g; Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA^h

We thank Dr. Wenzler and Dr. Danziger (1) for their comments on our recent paper (2) and appreciate their insightful perspective on the use of aminopenicillins for selected urinary tract infections (UTIs) caused by vancomycin-resistant enterococci. As they point out, our data provide clinical evidence to illustrate a widely known concept: site-specific pharmacokinetics/pharmacodynamics (PK/PD) should be considered in antimicrobial drug selection. The antimicrobial stewardship implications of this are particularly broad for UTIs, as these represent some of the most common bacterial infections encountered, resulting in significant antibiotic use and economic burdens across all health care settings (3). The implementation of urine-specific breakpoints is a critical issue that could dramatically improve the quality of antibiotic use for UTIs, with a clear potential to minimize the use of agents with excessive spectra and result in favorable patient outcomes. We support Wenzler and Danziger's call for greater clinical application of bench-to-bedside PK/PD principles in the management of uncomplicated UTIs.

REFERENCES

1. Wenzler E, Danziger LH. 2016. Urinary tract infections: resistance is futile. *Antimicrob Agents Chemother* 60:2596–2597. <http://dx.doi.org/10.1128/AAC.00006-16>.
2. Cole KA, Kenney RM, Perri MB, Dumkow LE, Samuel LP, Zervos MJ, Davis SL. 2015. Outcomes of aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections. *Antimicrob Agents Chemother* 59:7362–7366. <http://dx.doi.org/10.1128/AAC.01817-15>.
3. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection, and treatment options. *Nat Rev Microbiol* 13:269–284. <http://dx.doi.org/10.1038/nrmicro3432>.

Citation Kenney RM, Cole KA, Perri MB, Dumkow LE, Samuel LP, Zervos MJ, Davis SL. 2016. Reply to “Urinary tract infections: resistance is futile.” *Antimicrob Agents Chemother* 60:2598. doi:10.1128/AAC.00011-16.

Address correspondence to Rachel M. Kenney, rkenney1@hfhs.org.

This is a response to a letter by Wenzler and Danziger (doi:10.1128/AAC.00006-16).

Copyright © 2016, American Society for Microbiology. All Rights Reserved.